COMPASS Pathways成功达成第二项三期临床试验主要终点，评估Comp360裸盖菇素治疗难治性抑郁症疗效_老虎社区_美港股上老虎

COMPASS Pathways成功达成第二项三期临床试验主要终点，评估Comp360裸盖菇素治疗难治性抑郁症疗效

美股速递02-17

COMPASS Pathways plc（股票代码：CMPS）近日宣布，其针对难治性抑郁症治疗的创新疗法Comp360裸盖菇素，在第二项关键的三期临床试验中成功达到主要研究终点。这一突破性进展标志着该疗法在验证其安全性与有效性方面迈出了坚实一步，为全球数百万受难治性抑郁症困扰的患者带来了新的希望。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1102466641?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-17 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102466641","market":"us","top_or_hot":-1,"title":"COMPASS Pathways成功达成第二项三期临床试验主要终点，评估Comp360裸盖菇素治疗难治性抑郁症疗效","media":"美股速递","content":"<p>COMPASS Pathways plc（股票代码：CMPS）近日宣布，其针对难治性抑郁症治疗的创新疗法Comp360裸盖菇素，在第二项关键的三期临床试验中成功达到主要研究终点。这一突破性进展标志着该疗法在验证其安全性与有效性方面迈出了坚实一步，为全球数百万受难治性抑郁症困扰的患者带来了新的希望。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COMPASS Pathways成功达成第二项三期临床试验主要终点，评估Comp360裸盖菇素治疗难治性抑郁症疗效</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOMPASS Pathways成功达成第二项三期临床试验主要终点，评估Comp360裸盖菇素治疗难治性抑郁症疗效\n</h2>\n\n<h4 class=\"meta\">\n\n2026-02-17 19:31 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>COMPASS Pathways plc（股票代码：CMPS）近日宣布，其针对难治性抑郁症治疗的创新疗法Comp360裸盖菇素，在第二项关键的三期临床试验中成功达到主要研究终点。这一突破性进展标志着该疗法在验证其安全性与有效性方面迈出了坚实一步，为全球数百万受难治性抑郁症困扰的患者带来了新的希望。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPS","symbol_name":"COMPASS Pathways plc","start_time":0,"source_url":"","article_id":"1102466641","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102466641","pubTimestamp":1771327897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"COMPASS Pathways plc（股票代码：CMPS）近日宣布，其针对难治性抑郁症治疗的创新疗法Comp360裸盖菇素，在第二项关键的三期临床试验中成功达到主要研究终点。这一突破性进展标志着该疗法在验证其安全性与有效性方面迈出了坚实一步，为全球数百万受难治性抑郁症困扰的患者带来了新的希望。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CMPS":"COMPASS Pathways plc","BK4139":"生物科技"},"translate_title":"COMPASS Pathways successfully achieved the primary endpoint of the second phase III clinical trial to evaluate the efficacy of Comp360 psilocybin in the treatment of treatment-resistant depression","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPS":1},"content_text":"COMPASS Pathways plc（股票代码：CMPS）近日宣布，其针对难治性抑郁症治疗的创新疗法Comp360裸盖菇素，在第二项关键的三期临床试验中成功达到主要研究终点。这一突破性进展标志着该疗法在验证其安全性与有效性方面迈出了坚实一步，为全球数百万受难治性抑郁症困扰的患者带来了新的希望。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}